136 related articles for article (PubMed ID: 37759675)
1. Novel Anti-Melanoma Compounds Are Efficacious in A375 Cell Line Xenograft Melanoma Model in Nude Mice.
Velayutham S; Seerattan R; Sultan M; Seal T; Danthurthy S; Chinnappan B; Landi J; Pearl K; Singh A; Smalley KSM; Zaias J; Choi JY; Minond D
Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759675
[TBL] [Abstract][Full Text] [Related]
2. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
[TBL] [Abstract][Full Text] [Related]
3. Curcumin suppresses cell proliferation and triggers apoptosis in vemurafenib-resistant melanoma cells by downregulating the EGFR signaling pathway.
Chiu YJ; Yang JS; Tsai FJ; Chiu HY; Juan YN; Lo YH; Chiang JH
Environ Toxicol; 2022 Apr; 37(4):868-879. PubMed ID: 34994998
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2.
Wu T; Li C; Zhou C; Niu X; Li G; Zhou Y; Gu X; Cui H
Cell Biol Toxicol; 2023 Oct; 39(5):2381-2399. PubMed ID: 35648318
[TBL] [Abstract][Full Text] [Related]
5. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.
Feng JH; Nakagawa-Goto K; Lee KH; Shyur LF
Mol Cancer Ther; 2016 Jun; 15(6):1163-76. PubMed ID: 27048951
[TBL] [Abstract][Full Text] [Related]
6. Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf
Wu PK; Hong SK; Park JI
Cancer Lett; 2021 Apr; 502():25-33. PubMed ID: 33440231
[TBL] [Abstract][Full Text] [Related]
7. A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner.
Sutton SK; Carter DR; Kim P; Tan O; Arndt GM; Zhang XD; Baell J; Noll BD; Wang S; Kumar N; McArthur GA; Cheung BB; Marshall GM
Oncotarget; 2016 Aug; 7(32):52166-52178. PubMed ID: 27447557
[TBL] [Abstract][Full Text] [Related]
8. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
10. miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma.
Díaz-Martínez M; Benito-Jardón L; Alonso L; Koetz-Ploch L; Hernando E; Teixidó J
Cancer Res; 2018 Feb; 78(4):1017-1030. PubMed ID: 29229605
[TBL] [Abstract][Full Text] [Related]
11. Impact of carboplatin plus paclitaxel combined with endostar against A375 melanoma cells: An in vitro and in vivo analysis.
Zheng AW; Jia DD; Xia LM; Jin G; Wu H; Li T
Biomed Pharmacother; 2016 Oct; 83():1321-1326. PubMed ID: 27571875
[TBL] [Abstract][Full Text] [Related]
12. Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.
Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Zhao M; Zhang Y; Nelson SD; Russell TA; Dry SM; Singh AS; Chmielowski B; Li Y; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2017 Jul; 16(13):1288-1294. PubMed ID: 28622068
[TBL] [Abstract][Full Text] [Related]
13. Suppression effect of a dual cancer-specific oncolytic adenovirus on luciferase-labeled human melanoma cells in vitro and in vivo.
Li M; Zhu Y; Bai B; Fang J; Yao W; Li Y; Li S; Li X; Jin N; Jiang R
Cancer Biomark; 2021; 32(3):251-262. PubMed ID: 34459386
[TBL] [Abstract][Full Text] [Related]
14. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Acute Toxicity Studies of Novel Anti-Melanoma Compounds Downregulators of hnRNPH1/H2.
Velayutham S; Seal T; Danthurthy S; Zaias J; Smalley KSM; Minond D
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830718
[TBL] [Abstract][Full Text] [Related]
16. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
[TBL] [Abstract][Full Text] [Related]
17. BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
Paoluzzi L; Hanniford D; Sokolova E; Osman I; Darvishian F; Wang J; Bradner JE; Hernando E
Cancer Med; 2016 Jun; 5(6):1183-93. PubMed ID: 27169980
[TBL] [Abstract][Full Text] [Related]
18. Lidocaine inhibits melanoma cell proliferation by regulating ERK phosphorylation.
Chen J; Jiao Z; Wang A; Zhong W
J Cell Biochem; 2019 Apr; 120(4):6402-6408. PubMed ID: 30430626
[TBL] [Abstract][Full Text] [Related]
19. Oral administration of benzyl-isothiocyanate inhibits in vivo growth of subcutaneous xenograft tumors of human malignant melanoma A375.S2 cells.
Ni WY; Hsiao YP; Hsu SC; Hsueh SC; Chang CH; Ji BC; Yang JS; Lu HF; Chung JG
In Vivo; 2013; 27(5):623-6. PubMed ID: 23988897
[TBL] [Abstract][Full Text] [Related]
20. Variant G6PD levels promote tumor cell proliferation or apoptosis via the STAT3/5 pathway in the human melanoma xenograft mouse model.
Hu T; Zhang C; Tang Q; Su Y; Li B; Chen L; Zhang Z; Cai T; Zhu Y
BMC Cancer; 2013 May; 13():251. PubMed ID: 23693134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
